
Viridian Therapeutics Plans Concurrent Offerings of Notes, Common Stock, and Preferred Shares
Viridian Therapeutics Plans Concurrent Public Offerings of Convertible Senior Notes Due 2032, Common Shares, and Series B Non-Voting Convertible Preferred Stock Viridian Therapeutics (Nasdaq: VRDN), a clinical-stage biopharmaceutical company focused…












